MedDataX Logo

Bilateral Transversus Abdominis Plane Block and Postoperative Pain Intensity After Elective Cesarean Delivery

NCT ID: NCT00964600

Last Updated: 2010-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The patients planned to go under elective cesarean delivery under general anesthesia are randomly assigned to have either bilateral transversus abdominis plane (TAP) block or usual standard analgesics after cesarean. Pain score (Verbal Analog Scale VAS) and analgesic requirements are recorded. It's supposed that both are significantly reduced in patients undergoing TAP block.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

transversus abdominis block postoperative pain cesarean

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAP blockade

bilateral TAP blockade at the end of cesarean delivery

Group Type EXPERIMENTAL

TAP blockade

Intervention Type PROCEDURE

15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm

No TAP

These patients would have usual analgesic drugs after cesarean

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAP blockade

15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Elective cesarean delivery
2. Term pregnancies
3. General anesthesia
4. Pfannenstiel incision

Exclusion Criteria

1. No history of sensitivity to prescribed analgesic (Bupivacaine or related substances)
2. No preeclampsia
3. No history of psychologic disorders
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tehran University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MD ,associate Prof

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laleh Eslamian, MD

Role: PRINCIPAL_INVESTIGATOR

Tehran University of Medical Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sharati hospital

Tehran, Tehran Province, Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Laleh Eslamian, MD

Role: primary

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

825

Identifier Type: -

Identifier Source: org_study_id